International Stem Cell (ISCO) EBIT Margin (2010 - 2026)

International Stem Cell (ISCO) has reported EBIT Margin for 17 consecutive years, with 1.31% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin fell 813.0% year-over-year to 1.31% in Q2 2026; TTM through Jun 2026 was 0.9%, a 4.0% increase from a year earlier, with the FY2025 full-year figure at 2.93%, down 219.0% from the prior year.
• EBIT Margin was 1.31% for Q2 2026 at International Stem Cell, up from 14.52% in the prior quarter.
• Over five years, EBIT Margin peaked at 6.82% in Q2 2025 and troughed at 22.45% in Q4 2023.
• A 5-year average of 3.92% and a median of 1.31% in 2026 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin soared 3544 bps in 2022 and plunged 2496 bps in 2023, its largest moves.
• Over 5 years, EBIT Margin stood at 2.51% in 2022, then slumped by 994 bps to 22.45% in 2023, then surged by 109 bps to 2.09% in 2024, then slumped by 797 bps to 14.52% in 2025, then jumped by 91 bps to 1.31% in 2026.
• The last three EBIT Margin figures came in at 1.31% (Q2 2026), 14.52% (Q4 2025), and 3.97% (Q3 2025), per Business Quant data.